Potential investors have a wide range of options when it comes to biotech companies, which are making a huge splash in 2015. Here are some to keep an eye on: Propanc Health Group Corporation (PPCH). Propanc is a health care company at the development stage. It is currently working in the area of new treatments for chronic conditions, especially solid tumor cancers. The company was established in 2007, and its headquarters are in Melbourne, Australia.
Propanc announced recent data from early animal studies that used its patented formulas. Propanc’s in development proteolytic enzyme products (described as inactive precursors for enzymes by the company) did not produce any adverse effects in early studies and the company is ready to move on to the next stage of research. Propanc is a company website. “intends to undertake Phase I, II and III clinical trials to assess the safety and efficacy of our product in specific patient populations.”
Propanc’s long-term proenzyme therapy products, PRP and PRP–DCM, could be a game-changer in cancer care. They offer a viable option for long-term treatment without the high levels of toxicities associated with current treatments. These preliminary findings need to be confirmed by clinical trials. However, the company’s stated development objectives focus on solid tumors. The treatment options for these conditions are not available at the moment and can only be used to stabilize them or prolong their lives. Lung cancer, colorectal, ovarian, pancreatic, and liver cancer are all examples of solid tumor cancer.
The company says: “In each of these indications, there is a large market opportunity to capitalize on the limitations of current therapies.”
Although scientists are still not able to fully understand the mechanism by which proenzyme products fight cancer, early research suggests that they might be able to inhibit growth factors that can cause it. Propanc is currently investigating a method to shrink tumors using an injectable form PRP.
Propanc is also working with researchers to determine how Propanc’s products affect cancer cells. The company hopes to create new, patentable drugs through this research.
For more information about PPCH, please visit www.propanc.com.
